Halozyme Therapeutics, Inc. (HALO)
64.55
-0.81
(-1.24%)
USD |
NASDAQ |
Apr 27, 15:26
Halozyme Therapeutics PE Ratio : 25.90 for April 27, 2026
PE Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Price to Earnings Ratio (PE Ratio) Definition
The Price to Earnings Ratio (PE Ratio) is calculated by taking the stock price / EPS Diluted (TTM). This metric is considered a valuation metric that confirms whether the earnings of a company justifies the stock price. There isn't necesarily an optimum PE ratio, since different industries will have different ranges of PE Ratios. Because of this, PE Ratio is great to evaluate from a relative standpoint with other similar companies.
PE Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
PE Ratio Benchmarks
| Vertex Pharmaceuticals, Inc. | 27.95 |
| Johnson & Johnson | 26.07 |
| Eli Lilly & Co. | 38.73 |
| Baxter International, Inc. | -- |
| Glaukos Corp. | -- |
PE Ratio Related Metrics
| PS Ratio | 5.671 |
| Price to Book Value | 156.06 |
| Price to Free Cash Flow | 12.29 |
| Price | 64.55 |
| Earnings Yield | 3.86% |
| Market Cap | 7.618B |
| Operating PE Ratio | 9.703 |
| Normalized PE Ratio | 14.06 |